SCHEMBL25755715

SCHEMBL25755715

CCn1nc(C)c2scc(Br)c2c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 4/20 0.36
ADORA3 P0DMS8 2/20 0.36
PDE4B Q07343 5/20 0.35
ADORA2A P29274 5/20 0.35
PDE4A P27815 4/20 0.35
PDE4C Q08493 4/20 0.35
PDE4D Q08499 4/20 0.35
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
ADORA2B P29275 2/20 0.34
MAPT P10636 3/20 0.33
GAA P10253 1/20 0.33
TP53 P04637 2/20 0.33
POLB P06746 1/20 0.33
THRB P10828 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
KDM4E B2RXH2 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25755717 0.73 PDE4A (0.39) ADORA1ADORA3PDE4BADORA2APDE4A
SCHEMBL25755170 0.70 KMT2A (0.38) MAPTGAASMN1; SMN2LMNARAB9A
SCHEMBL18337632 0.70 ALDH1A1 (0.35) ADORA1ADORA3PDE4BADORA2APDE4A
SCHEMBL25754660 0.66 TSHR (0.33)
SCHEMBL16045741 0.65 GPR35 (0.33)
SCHEMBL25755714 0.64 PDPK1 (0.35) TP53L3MBTL1
SCHEMBL22729431 0.64 GPR35 (0.39)
SCHEMBL16047264 0.63 ADORA1 (0.48) ADORA1ADORA3PDE4BADORA2APDE4A
SCHEMBL18335764 0.62 ALDH1A1 (0.35) PDE4BADORA2APDE4APDE4CPDE4D
SCHEMBL12877767 0.61 LMNA (0.64) MAPTPOLBSMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
EP-4448514-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2024-10-23 EP disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 ADORA1 4716/4885ADORA3 4610/4885PDE4B 4283/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 ADORA1 4716/4885ADORA3 4610/4885PDE4B 4283/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 ADORA1 4716/4885ADORA3 4610/4885PDE4B 4283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.